NIH awarded $3M to BioSensics to Develop First-in-kind Wearable Sensor

BioSensics is pleased to announce a $3 million, three-year award from the U.S. National Institutes of Health (NIH). This grant will support the development of a groundbreaking wearable device designed for tracking speech activities and biomarkers during daily routines.

The PAMSys Voice™ wearable sensor incorporates bidirectional microphones for synchronized audio data capture, as well as an accelerometer and gyroscope to record chest motion data. This innovative patented device seamlessly integrates audio and motion monitoring, making it a unique wearable sensor for remote tracking of speech activities and biomarkers, coupled with precision actigraphy and fall detection capabilities.

The NIH grant is aimed at advancing the development of PAMSys Voice™ and validating its utilization as a robust tool for the early identification of cognitive decline and the remote tracking of cognitive-motor function in individuals with dementia and Alzheimer's disease. The project involves collaboration with Drs. Bijan Najafi and Michele York from Baylor College of Medicine. 

A limited number of PAMSys Voice™ sensors will be available for research purposes in early 2024. If you wish to explore possibilities for collaboration and partnership, please contact us.

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of its solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consultation services, such as study design and protocol development, in addition to statistical analysis. Furthermore, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics remote measure technologies was selected by the NIH for use in clinical trials involving people with rare diseases.